Skip to main content

Table 6 Anticancer treatments received by patients after discontinuing study treatment, safety population

From: Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

INN class/preferred terma Cohort 1: pertuzumab, trastuzumab, and vinorelbine N = 106b n = 90c
HER2-targeted treatmentd,e (also counted in individual classes)
 Patients who received any treatment 81 (90.0%)
  Lapatinib 27 (30.0%)
  Neratinib 1 (1.1%)
  Pertuzumab 10 (11.1%)
  Trastuzumab 57 (63.3%)
  Trastuzumab emtansine 17 (18.9%)
Alkylating agents
 Patients who received any treatment 6 (6.7%)
  Cyclophosphamide 6 (6.7%)
Antiestrogens
 Patients who received any treatment 6 (6.7%)
  Fulvestrant 2 (2.2%)
  Tamoxifen 4 (4.4%)
Antimetabolites
 Patients who received any treatment 32 (35.6%)
  Capecitabine 30 (33.3%)
  Fluorouracil 1 (1.1%)
  Gemcitabine 3 (3.3%)
Antineoplastic agentsf
 Patients who received any treatment 19 (21.1%)
  Eribulin 3 (3.3%)
  Temsirolimus 1 (1.1%)
  Trastuzumab emtansine 17 (18.9%)
Aromatase inhibitors
 Patients who received any treatment 15 (16.7%)
  Anastrozole 5 (5.6%)
  Exemestane 5 (5.6%)
  Letrozole 5 (5.6%)
Cytotoxic antibiotics
 Patients who received any treatment 9 (10.0%)
  Doxorubicin 4 (4.4%)
  Epirubicin 4 (4.4%)
  Mitoxantrone 1 (1.1%)
Gonadotrophin and analogs
 Patients who received any treatment 2 (2.2%)
  Leuprorelin 2 (2.2%)
Monoclonal antibodies
 Patients who received any treatment 57 (63.3%)
  Denosumab 2 (2.2%)
  Pertuzumab 10 (11.1%)
  Trastuzumab 57 (63.3%)
Penicillins
 Patients who received any treatment 1 (1.1%)
  Dicloxacillin 1 (1.1%)
Platinum compounds
 Patients who received any treatment 5 (5.6%)
  Carboplatin 3 (3.3%)
  Cisplatin 2 (2.2%)
Surgical and medical procedures
 Patients who received any treatment 22 (24.4%)
  Brain tumor operation 1 (1.1%)
  Breast operation 1 (1.1%)
  Gamma radiation therapy to brain 1 (1.1%)
  Lesion excision 1 (1.1%)
  Lymphadenectomy 1 (1.1%)
  Malignant tumor excision 2 (2.2%)
  Mastectomy 5 (5.6%)
  Radiotherapy 8 (8.9%)
  Radiotherapy to brain 5 (5.6%)
  Radiotherapy to lung 1 (1.1%)
  Radiotherapy to lymph nodes 1 (1.1%)
Taxanes
 Patients who received any treatment 24 (26.7%)
  Docetaxel 10 (11.1%)
  Paclitaxel 15 (16.7%)
Topoisomerase inhibitors
 Patients who received any treatment 1 (1.1%)
  Etoposide 1 (1.1%)
Tyrosine kinase inhibitors
 Patients who received any treatment 28 (31.1%)
  Lapatinib 27 (30.0%)
  Neratinib 1 (1.1%)
Vinca alkaloids
 Patients who received any treatment 11 (12.2%)
  Vinorelbineg 11 (12.2%)
Combinationsd (also counted in individual classes)
 Patients who received any treatment 5 (5.6%)
  Cisplatin/cyclophosphamide/epirubicin/etoposide/fluorouracil 1 (1.1%)
  Dicloxacillin/doxorubicin 1 (1.1%)
  Capecitabine/lapatinib/trastuzumab 1 (1.1%)
  Carboplatin/gemcitabine 1 (1.1%)
  Carboplatin/trastuzumab 1 (1.1%)
  1. Data reported are number (%).
  2. aINN classes are presented alphabetically and preferred terms are sorted within INN classes alphabetically
  3. bNumber of patients in the safety population
  4. cNumber of patients who received at least one anticancer treatment after discontinuing study treatment. Percentages are based on n. Patients may have received more than one anticancer treatment after discontinuing study treatment. Some therapies began before the last study treatment was received
  5. dAll preferred terms within the “HER2-targeted treatment” and “Combinations” summaries are also included in their respective INN classes
  6. eThe “HER2-targeted treatment” summary is a reclassification of specific preferred terms, identified by the medical team
  7. fThe “Antineoplastic agents” summary includes any drug used to treat cancers that cannot be assigned to a more specific pharmacological class
  8. gEleven patients had vinorelbine (re)introduced after study treatment was discontinued: six patients who had stopped study treatment due to an adverse event/unacceptable toxicity (three of whom had not received on study vinorelbine due to AE with pertuzumab and/or trastuzumab administration and had discontinued study treatment before receiving vinorelbine as an anticancer therapy); three patients who had stopped study treatment due to administrative/other reasons; and two patients who had stopped study treatment due to disease progression